EGFR and breast cancer: The high frequency of TP53 mutations (in 3/4 BC and 2/2 HGSC samples) is in agreement with previous studies [10, 28], while other common drivers, such as EGFR, PTEN, CDH1, CDKN2A, APC, ATM, and MAP2K1, were found to be mutated in our study.